There are currently three BTK inhibitors on the market worldwide, and Calquence (Acalabrutinib) stands out for its safety and fewer adverse reactions. Acalabrutinib is a second-generation BTK inhibitor that can exert its therapeutic effect by blocking the enzymes required for tumor cell replication and metastasis. You can save Up to 50% off on Calquence cost from Medixo Centre.